EP Patent

EP0261693A1 — Treated lipid regulator

Assigned to Warner Lambert Co LLC · Expires 1988-03-30 · 38y expired

What this patent protects

Cholestyramine can be administered orally either alone or in combination with one or more other beneficial agent(s) in compositions in which the cholestyramine has been suitably pretreated.

USPTO Abstract

Cholestyramine can be administered orally either alone or in combination with one or more other beneficial agent(s) in compositions in which the cholestyramine has been suitably pretreated.

Drugs covered by this patent

Patent Metadata

Patent number
EP0261693A1
Jurisdiction
EP
Classification
—
Expires
1988-03-30
Drug substance claim
No
Drug product claim
No
Assignee
Warner Lambert Co LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.